Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)

Cat. No.: HY-P992014: Data Sheet
FAQs
Technical Support

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

사이즈		재고
MOQ		Minimum order quantity
1 mg		견적 받기
5 mg		견적 받기
10 mg		견적 받기
Other size		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
순도&문서
References
고객리뷰

제품 설명

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3^[1].

Isotype

Mouse IgG2a kappa

Recommend Isotype Controls

Mouse IgG2a kappa, Isotype Control

Species Reactivity

Human/Mouse/Monkey

In Vitro

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) specifically binds to mouse, human, and marmoset CXCR3 expressed on transfected cells and primary immune cells^[1].
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) binds to an epitope within amino acid residues 23 to 44 of human CXCR3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) (2-5 mg/kg; i.v.; single/weekly; 7-21 days) increases pancreatic islet allograft survival in mice, with a single 5 mg/kg dose boosting mean graft survival time from 17 to 33 days, and weekly 2 mg/kg doses achieving 35 days MST with long-term survival in some animals^[1].
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) (0.5-10 mg/kg; i.v.; single dose) dose-dependently depletes CXCR3-expressing CD4⁺, CD8⁺, and B cells in mice, with complete depletion at doses ≥ 2 mg/kg lasting for more than 3 weeks^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (streptozotocin-induced diabetic, pancreatic islet allograft recipients)^[1]
Dosage:	5 mg/kg (single pre-transplant dose); 2 mg/kg (weekly post-transplant doses); 2 mg/kg (weekly post-transplant + daily rapamycin for 7 days)
Administration:	i.v.; single dose (4-5 hours pre-transplant); i.v.; weekly (days 0,7,14,21 post-transplant); i.v.; weekly (days 0,7,14,21 post-transplant) + p.o.; daily (rapamycin, 7 days post-transplant)
Result:	Increased mean survival time (MST) of islet grafts from 17 to 33 days. Increased MST of islet grafts to 35 days, with 2 out of 7 mice showing graft survival >100 days. Resulted in 50% graft survival at 60 days.

Animal Model:	C57BL/6^[1]
Dosage:	0.5-10 mg/kg
Administration:	i.v.; single dose
Result:	Almost completely depleted CD4+/CXCR3+, CD8+/CXCR3+, and B220+/CXCR3+ cells within 4 days at doses of 2 mg/kg and higher; 0.5 mg/kg had no depletion effect. Maintained depletion of CXCR3+ cells for more than 3 weeks after a single 5 mg/kg dose. Reduced effector CD4+ T-cells (CD44high/CD62Llow) and memory CD4+ T-cells (CD44high/CD62Lhigh) from 27.1% to 13.5% relative to isotype control-treated mice after a single 5 mg/kg dose.

Gene ID

2833 [NCBI]

Accession

P49682-1

Target

CXCR3/GPR9/CD183

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

SMILES

[Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)]

선적

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

产品图

순도&문서

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Charles Reay Mackay, et al. Anticorps et leurs utilisations. WO2014186842A1. 2014.